4/A: Aileron Therapeutics Director Corrects Stock Option Exercise Price in Amended SEC Filing
SEC Filing (Form 4/A Amendment)
Josef H. von Rickenbach, a director of Aileron Therapeutics, filed an amended SEC Form 4 to correct the exercise price of stock options granted on February 28, 2024.
Summary
- Josef H. von Rickenbach, a director of Aileron Therapeutics, filed an amendment to a previously submitted Form 4 with the SEC.
- The amendment corrects the exercise price of stock options granted to von Rickenbach on February 28, 2024.
- The exercise price was initially reported as $4.80 but has been corrected to $4.72, reflecting the adjusted closing price of Aileron Therapeutics' stock on the grant date.
- The options, for 2,725 shares, vest fully on the earlier of February 28, 2025, or the date of the Issuer's 2024 Annual Meeting of Stockholders.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company.
Industry Context
Form 4 filings are standard practice for company insiders (directors, officers, and 10% owners) to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | Date of the original transaction (grant of stock options) and adjusted closing price of the Issuer's stock. |
| 03/01/2024 | Date of original Form 4 filing. |
| 02/28/2025 | Date of full vesting of stock options (or earlier if 2024 Annual Meeting of Stockholders occurs before). |
| 04/10/2024 | Date of the amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.